Spearheaded by NIH's National Institute of General Medical Sciences and originally funded from 2000 to 2005, the PGRN's record of success includes discoveries about medications used for such serious diseases as cancer, heart disease, and asthma. To read about more of these successes, go to http://www.nigms.nih.gov/pharmacogenetics/five-year.html.
"By showing how our genes influence our responses to medicines, the PGRN is making critical advances that will maximize the benefits of treatment while minimizing adverse side effects. This will ultimately improve patient outcomes and reduce health care costs," said NIH Director Elias A. Zerhouni, MD.
The network is supported by nine NIH components: NIGMS; the National Heart, Lung, and Blood Institute; the National Cancer Institute; the National Human Genome Research Institute; the National Institute of Environmental Health Sciences; the National Library of Medicine; the National Institute on Drug Abuse; the National Institute of Mental Health; and the Office of Research on Women's Health.
The new network consists of 12 groups, listed below alphabetically by principal investigator. Also included are the anticipated 5-year totals for each award.
The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB)--$13.7 million provided by NIGMS, NHGRI, NHLBI, and NLM to develop and operate this online resource, which serves as a shared information library for pha
Contact: Alisa Zapp Machalek
NIH/National Institute of General Medical Sciences